CRSP vs. NBIX, EXEL, MRNA, QGEN, TECH, RVMD, RGEN, HALO, ADMA, and PCVX
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Neurocrine Biosciences (NBIX), Exelixis (EXEL), Moderna (MRNA), Qiagen (QGEN), Bio-Techne (TECH), Revolution Medicines (RVMD), Repligen (RGEN), Halozyme Therapeutics (HALO), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics vs. Its Competitors
CRISPR Therapeutics (NASDAQ:CRSP) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
CRISPR Therapeutics presently has a consensus price target of $71.75, indicating a potential upside of 73.48%. Neurocrine Biosciences has a consensus price target of $162.00, indicating a potential upside of 30.24%. Given CRISPR Therapeutics' higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.
Neurocrine Biosciences received 559 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 64.37% of users gave CRISPR Therapeutics an outperform vote.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
CRISPR Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
In the previous week, Neurocrine Biosciences had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 13 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.79 beat Neurocrine Biosciences' score of 0.76 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
Neurocrine Biosciences has a net margin of 14.49% compared to CRISPR Therapeutics' net margin of -981.54%. Neurocrine Biosciences' return on equity of 13.38% beat CRISPR Therapeutics' return on equity.
Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Neurocrine Biosciences beats CRISPR Therapeutics on 14 of the 18 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
CRISPR Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRSP) was last updated on 6/13/2025 by MarketBeat.com Staff